Trustees of Princeton University purchased a new position in shares of Teladoc Inc (NYSE:TDOC) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 43,098 shares of the health services provider’s stock, valued at approximately $2,502,000. Teladoc accounts for approximately 2.6% of Trustees of Princeton University’s investment portfolio, making the stock its 6th largest position. Trustees of Princeton University owned 0.06% of Teladoc as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in TDOC. Wells Fargo & Company MN lifted its holdings in Teladoc by 20.2% in the 1st quarter. Wells Fargo & Company MN now owns 616,056 shares of the health services provider’s stock worth $24,826,000 after buying an additional 103,626 shares in the last quarter. Rhumbline Advisers lifted its holdings in Teladoc by 4.0% in the 1st quarter. Rhumbline Advisers now owns 53,616 shares of the health services provider’s stock worth $2,161,000 after buying an additional 2,065 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Teladoc by 68.8% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,874 shares of the health services provider’s stock worth $116,000 after buying an additional 1,171 shares in the last quarter. American Century Companies Inc. lifted its holdings in Teladoc by 5.9% in the 1st quarter. American Century Companies Inc. now owns 182,056 shares of the health services provider’s stock worth $7,337,000 after buying an additional 10,090 shares in the last quarter. Finally, Swiss National Bank lifted its holdings in Teladoc by 1.7% in the 1st quarter. Swiss National Bank now owns 94,400 shares of the health services provider’s stock worth $3,804,000 after buying an additional 1,600 shares in the last quarter.

A number of equities analysts have commented on TDOC shares. KeyCorp boosted their price objective on shares of Teladoc from $74.00 to $90.00 and gave the stock an “overweight” rating in a report on Monday, August 27th. Berenberg Bank started coverage on shares of Teladoc in a report on Monday, July 9th. They issued a “buy” rating and a $72.00 price objective on the stock. Jefferies Financial Group set a $74.00 price objective on shares of Teladoc and gave the stock a “buy” rating in a report on Wednesday, July 11th. Leerink Swann started coverage on shares of Teladoc in a report on Thursday, August 16th. They issued an “outperform” rating and a $90.00 price objective on the stock. Finally, Wells Fargo & Co reiterated a “buy” rating and issued a $70.00 price objective on shares of Teladoc in a report on Thursday, August 2nd. One research analyst has rated the stock with a sell rating, five have given a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Teladoc currently has a consensus rating of “Buy” and a consensus target price of $65.10.

In related news, CEO Jason N. Gorevic sold 25,000 shares of the stock in a transaction dated Friday, June 15th. The shares were sold at an average price of $60.21, for a total transaction of $1,505,250.00. Following the sale, the chief executive officer now owns 611,184 shares in the company, valued at $36,799,388.64. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, President Peter A. Mcclennen sold 91,072 shares of the stock in a transaction dated Monday, July 16th. The stock was sold at an average price of $65.84, for a total transaction of $5,996,180.48. Following the sale, the president now owns 61,660 shares in the company, valued at approximately $4,059,694.40. The disclosure for this sale can be found here. In the last 90 days, insiders sold 267,497 shares of company stock worth $17,613,519. Company insiders own 3.95% of the company’s stock.

Shares of Teladoc stock opened at $77.80 on Thursday. The stock has a market capitalization of $5.43 billion, a PE ratio of -47.15 and a beta of 0.58. The company has a current ratio of 3.14, a quick ratio of 3.14 and a debt-to-equity ratio of 0.58. Teladoc Inc has a 1 year low of $27.30 and a 1 year high of $79.64.

Teladoc (NYSE:TDOC) last issued its earnings results on Wednesday, August 1st. The health services provider reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.01. The business had revenue of $94.60 million for the quarter, compared to analyst estimates of $91.56 million. Teladoc had a negative net margin of 37.78% and a negative return on equity of 19.10%. The company’s revenue for the quarter was up 112.1% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.28) EPS. sell-side analysts forecast that Teladoc Inc will post -1.51 earnings per share for the current year.

About Teladoc

Teladoc, Inc provides telehealth services worldwide. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.

Recommended Story: Stock Symbols Definition, Examples, Lookup

Institutional Ownership by Quarter for Teladoc (NYSE:TDOC)

Receive News & Ratings for Teladoc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc and related companies with MarketBeat.com's FREE daily email newsletter.